Welcome to World Class Retina Care

Our practice was established in 1980 in central Phoenix. Since then, we have grown to include more than 35 locations throughout Arizona, providing improved access to the highest quality medical care. We are proud to have become Arizona’s largest and most experienced ophthalmology practice focused specifically on the diagnosis and management of the retina and vitreous.

At RCA, we believe in providing you with professional, attentive, and personal care while utilizing the latest technology and treatments. We accept new patients every day, and urgent or emergency referrals are seen the same day.

Find Your Location Today

Take charge of your eye health!

Making healthy choices and getting regular eye exams can help reduce a person’s risk of vision loss. we encourage everyone to take charge of their eye health and preserve their sight by following some simple tips.

Click here for more!

Latest News From RCA

Dr. Pravin U. Dugel: Anatomy in HAWK and HARRIER

Retina Subspecialty Day Coverage – American Academy of Ophthalmology 2018 Series: 2018 Pravin U. Dugel, MD   Channels: Retina Pravin U. Dugel, MD, details the results of the phase 3 HAWK and HARRIER studies evaluating brolucizumab (Novartis) for the treatment of wet age-related macular degeneration. Dr. Dugel compares data from the 96-week endpoint to the… Read More »

Retina CME Opportunity: Intravitreal Interventions: Volume 7, Number 4

Intravitreal Interventions: Volume 7, Number 4 Click Here to Start Author(s)/Faculty: Rishi P. Singh, MD; Ahmad Al-Moujahed, MD, MPH; Sarina M. Amin, MD; Malvika Arya, BS; Pravin U. Dugel, MD; Jorge A. Fortun, MD; Andrew A. Moshfeghi, MD, MBA; Nadia K. Waheed, MD, MPH   Release Date: 10/30/2018 Expiration Date: 10/29/2019 Credit Type: CME Number… Read More »

Dr. Pravin U. Dugel: Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD

October 27, 2018 10:09 ET | Source:  Novartis International AG Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central subfield thickness demonstrated at year one were reaffirmed at year two with brolucizumab 6 mg versus aflibercept Robust visual gains shown in… Read More »